A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma Journal Article
| Authors: | Lowery, M.; Shah, M. A.; Smyth, E.; Epstein, A.; Segal, A.; Rosengarten, O.; Isacson, R.; Drukker, L.; Keinan, A.; Rachkiman, M.; Reissman, P.; Gabizon, A.; Kelsen, D.; O'Reilly, E. M. |
| Article Title: | A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma |
| Abstract: | Introduction: There are approximately 40,000 new cases of pancreatic adenocarcinoma diagnosed in the USA each year. It is estimated that 5-10% of all patients with pancreatic cancer have a first-degree relative with the disease, while up to 20% of cases have a hereditary component. Individuals who carry a germline mutation in the BRCA 1 or 2 genes have an increased lifetime risk of developing pancreatic adenocarcinoma when compared with the general population. Case report: Here, we present a case of metastatic pancreatic adenocarcinoma arising in a 67-year-old carrier of a BRCA 1 germline mutation. Discussion: In patients with known BRCA 1 or 2 mutation-associated pancreatic adenocarcinoma, the addition of a DNA cross-linking agent such as cisplatin, oxaliplatin, or mitomycin to a standard gemcitabine chemotherapy backbone should be considered. Poly ADP-ribose inhibitors are a novel class of drug, which have demonstrated promising efficacy in trials of BRCA 1 and 2 mutant breast and ovarian cancer, and are currently undergoing prospective evaluation in advanced pancreatic cancer. © Springer Science+Business Media, LLC 2010. |
| Keywords: | immunohistochemistry; human tissue; treatment outcome; treatment response; aged; gene mutation; cancer recurrence; case report; cisplatin; doxorubicin; fluorouracil; cancer combination chemotherapy; cancer risk; treatment duration; gemcitabine; cancer adjuvant therapy; pancreatic neoplasms; sentinel lymph node biopsy; adenocarcinoma; carboplatin; computer assisted tomography; antineoplastic combined chemotherapy protocols; ca 19-9 antigen; genetic association; weight reduction; cyclophosphamide; steroid; angiosarcoma; brca1 protein; brca2 protein; heterozygote; risk assessment; irinotecan; drug hypersensitivity; dyspnea; oncogene; liver metastasis; folinic acid; tamoxifen; pancreas adenocarcinoma; disease duration; pancreatic adenocarcinoma; mitomycin; oxaliplatin; deoxycytidine; organoplatinum compounds; liver biopsy; intraductal carcinoma; oxygen saturation; germ-line mutation; jew; olaparib; steroid therapy; parp inhibitor; skin test; brca 1; brca 2; hereditary pancreatic cancer; poly adp-ribose inhibitor; epigastric discomfort |
| Journal Title: | Journal of Gastrointestinal Cancer |
| Volume: | 42 |
| Issue: | 3 |
| ISSN: | 1941-6628 |
| Publisher: | Springer |
| Date Published: | 2011-09-01 |
| Start Page: | 160 |
| End Page: | 164 |
| Language: | English |
| DOI: | 10.1007/s12029-010-9197-1 |
| PROVIDER: | scopus |
| PUBMED: | 20711688 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 9 December 2011" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work